Disease Trajectories & Progression
Modeling disease progression and clinical outcomes in Parkinson's disease using longitudinal cohorts, survival analysis, and clinically grounded prediction frameworks.
Neurology · AI · Clinical Research
Shaping how AI transforms Parkinson's disease care
I'm a movement disorders neurologist using AI and large-scale data to model disease trajectories, predict outcomes, and extend specialist-level expertise beyond the clinic.
Research
Research Themes
Clinical Bioinformatics & NLP
Clinical bioinformatics and natural language processing to extract meaningful outcomes from electronic health records.
Technology-Enabled Outcomes
Technology-enabled and patient-centered outcome measurement in movement disorders.
Speaking
Selected Talks
May 2026
Phoenix, AZ
From Big Data to Personalized Care
7th World Parkinson Congress
February 2026
Houston, TX
Is Artificial Intelligence Relevant for the Diagnosis of Parkinson's Disease?
6th Pan American PD & Movement Disorders Congress
September 2025
Omaha, NE
Rethinking Falls in Parkinson's Disease: A Bioinformatics Approach Rooted in Clinical Insight
Neurology Grand Rounds, University of Nebraska
Publications
Selected Publications
01
Vizcarra JA, Yarlagadda S, Xie K, Ellis CA, Spindler M, Hammer LH. AI in the Diagnosis and Quantitative Phenotyping of Hyperkinetic Movement Disorders: A Systematic Review.
Journal of Clinical Medicine · 2024
02
Vizcarra JA, Casey HL, Hamedani AG, Gomez CM. Reliability of remote video ratings of the scale for assessment and rating of ataxia.
Parkinsonism & Related Disorders · 2025
03
Vizcarra JA, Sánchez-Ferro Á, Maetzler W, et al. The Parkinson's Disease e-Diary: Developing a Clinical and Research Tool for the Digital Age.
Movement Disorders · 2019
04
Vizcarra JA, Situ-Kcomt M, Artusi CA, et al. Subthalamic Deep Brain Stimulation and Levodopa in Parkinson's Disease: A Meta-Analysis of Combined Effects.
Journal of Neurology · 2019
05
Vizcarra JA, Lang AE, Sethi KD, Espay AJ. Vascular Parkinsonism: Deconstructing a Syndrome.
Movement Disorders · 2015
Writing
Recent Writing
The FDA's new Bayesian guidance changes what clinical trials can ask and answer. For Parkinson's disease, where proving disease modification has always been the hardest problem, this matters more than most.
Read more →The Mobilise-D consortium validated 24 digital mobility outcomes in 601 people with Parkinson's disease across five European sites. The data make a careful case for rethinking how trials measure what matters.
Read more →A 35-center randomized trial tested whether wearable-guided medication adjustment improved outcomes in Parkinson's disease. The result opens questions about where these tools work best.
Read more →Why real-world workflow adoption, not just model performance, will determine impact for Parkinson's AI in primary care.
Read more →Contact
Get in Touch
For speaking invitations, research collaboration, or academic inquiries.
Contact Me